Glenmark unit gets tentative FDA nod for 2 drugs

17008 Investors following Glenmark. Share this News with them.

0

Like this story, share it with millions of investors on M3

Glenmark unit gets tentative FDA nod for 2 drugs

Glenmark Generics Ltd, a unit of Glenmark Pharmaceuticals Ltd, said on Thursday its US unit received a tentative approval from the USFDA for two drugs.

Post your opinion here

 

0

Tweet

Share on Tumblr

Watch CNBC-TV18 live only on MYTV >> RELATED NEWS Glenmark Pharma has target of Rs 310: Rohit Shinde Stay invested in Glenmark Pharma: Mohindar Hold Glenmark Pharma, says Varun Daga Buy Glenmark Pharma at Rs 210-215: Gujral Buy Glenmark Pharma, target Rs 319: Sharekhan ALSO READ See latest News about Glenmark See previous management interviews See what other Experts & Brokerages are saying about Glenmark

Glenmark Generics Ltd , a unit of Glenmark Pharmaceuticals Ltd, said on Thursday its US unit received a tentative approval from the USFDA for two drugs.

The estimated market size of one of the drugs Pramipexole Dihydrochloride, the generic version of Boehringer Ingelheim's Mirapex tablets, is estimated at USD487 million, it said in a statement.

The second drug, Atomoxetine Hydrochloride, is used in the treatment of attention deficit or hyperactivity disorder, and has an estimated market size of USD498 million, it added.